Outcome events and quality parameters of recombinant tissue plasminogen activator treatment
| Patients (n) | % (95% CI) | |
|---|---|---|
| mRS, modified Rankin Scale. | ||
| Considerable earlyimprovement | 33 | 50.8 (38.1 to 63.4) |
| mRS ⩽2 (3 months) | 41 | 63.1 (50.2 to 74.7) |
| Symptomatic intracranial haemorrhage | 0 | 0 (0 to 5.6) |
| Mortality (3 months) | 11 | 16.9 (8.8 to 28.3) |
| Onset to treatment <90 min | 1 | 1.5 (0 to 8.3) |
| Door-to-needle time <45 min | 6 | 9.2 (3.5 to 19) |